Evidence map›Paper›PMID 40842022›Full record

ArticleCPT: pharmacometrics & systems pharmacology2025

A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules.

Maria M Posada, Karen B Schneck, Bridget L Morse, Luc R A Rougee, Lai San Tham, Jessica F Rehmel, Brian Thompson, Stephen D Stamatis, Stephen D Hall, Gemma L Dickinson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria M PosadaGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0003-4645-0763
Karen B SchneckGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0002-9229-4987
Bridget L MorseGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.
Luc R A RougeeGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.
Lai San ThamGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Lilly Centre for Clinical Pharmacology, Singapore, Singapore.ORCID 0000-0002-1249-8526
Jessica F RehmelGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0009-0001-5049-1018
Brian ThompsonGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0003-3055-9414
Stephen D StamatisSynthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0001-9919-2011
Stephen D HallGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.
Gemma L DickinsonGlobal PK/PD and Pharmacometrics, Eli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0009-0008-1808-6881

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

Dulaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered molecules utilizing a combination of population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) modeling approaches. In clinical studies, the gastric emptying delay (GED) was evaluated in healthy participants and patients with T2DM at various dose levels of dulaglutide. A PopPK model estimated the exposure-dependent delay in gastric emptying, which was then input into the orally administered small molecule PBPK models. These PBPK models, informed by internal clinical studies and publicly available data, quantified the effect of dulaglutide-induced GED on the area under the curve (AUC), maximum concentration (C

Indexed as

Diabetes Mellitus, Type 2Gastric EmptyingGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsModels, BiologicalRecombinant Fusion ProteinsAdministration, OralAdultArea Under CurveFemaleGlucagon-Like Peptide-1 Receptor AgonistsHumansMaleMiddle AgeddulaglutideGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion Proteinsdrug–drug interactionsdulaglutidegastric emptying delayGLP1 receptor agonistPBPK

Identifiers

PMID40842022
PMCPMC12706417

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.